Eli Lilly announced today the first positive results of two Phase 3 clinical trials evaluating the once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time, and in others using multiple daily insulin injections.

In target-therapy clinical trials, efsitora showed a non-inferior reduction in A1C compared with the world's most commonly used daily basal insulins.

' The results [from the two trials] are an important milestone for the diabetes community and demonstrate that efficacy as a weekly insulin provides equivalent glycemic control to daily basal insulins', said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly.


Copyright (c) 2024 CercleFinance.com. All rights reserved.